SecurityGNMX / Aevi Genomic Medicine, Inc. (58436Q203)
IndustryBiological Products, Except Diagnostic Substances (Biotech)
Common Stock Shares Outstanding59,340,731 shares (as of 2018-06-30)
Total Insiders14
Total Directors9
Total Officers4

Stock Insider Trading (from SEC Form 4)

Aevi Genomic Medicine, Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

GNMX / Aevi Genomic Medicine, Inc. insiders include Applebaum Scott, GANTZ WILBUR H, Duncan Barbara Gayle, BARER SOL J, BAUER EUGENE A, HARPER PHILIP R NEIL GARRY ARTHUR, GRANO JOSEPH J JR, Children's Hospital of Philadelphia Foundation, CLEMOW ALASTAIR J, BLECH ISAAC, Piper Brian, Bayley Matthew D, and COLA MICHAEL F, .

Insider Roster

Insider Dir Off 10% Shares Owned
BARER SOL J Director
X 4,098,752
Children's Hospital of Philadelphia Foundation 10% Owner
X 18,424,036
Bayley Matthew D Director
X
COLA MICHAEL F President and CEO, Director
X X
NEIL GARRY ARTHUR Chief Scientific Officer
X
Piper Brian CFO & Corporate Secretary
X
GRANO JOSEPH J JR Director
X
BAUER EUGENE A Director
X
CLEMOW ALASTAIR J Director
X
Duncan Barbara Gayle Director
X
GANTZ WILBUR H Director
X 71,073
HARPER PHILIP R 10% Owner
X 5,179,819
BLECH ISAAC Director
X
Applebaum Scott Chief Legal Officer
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-08-15 4 Children's Hospital of Philadelphia Foundation P D 0.96 2,551,020 18,424,036 17,687,075
2018-08-15 4 BARER SOL J By: Barer & Son Capital LLC P I 0.96 2,551,020 4,098,752 3,934,802
2017-10-17 4 BARER SOL J P D 1.26 421,032 1,547,732 1,950,142
2017-10-17 4 GRANO JOSEPH J JR P D 1.26 -39,683 113,847 143,447
2017-10-17 4 NEIL GARRY ARTHUR P D 1.26 75,000 114,774 144,615
2017-10-17 4 GANTZ WILBUR H P D 1.26 39,683 71,073 89,552
2017-10-17 4 Duncan Barbara Gayle P D 1.26 59,524 59,524 75,000
2017-10-17 4 CLEMOW ALASTAIR J P D 1.26 19,841 57,536 72,495
2017-10-17 4 BAUER EUGENE A P D 1.26 19,841 165,715 208,801
2017-10-17 4 COLA MICHAEL F P D 1.26 119,047 218,483 275,289
2017-09-01 4 HARPER PHILIP R P D 1.2 83,775 5,179,819 6,215,783
2017-08-23 4 HARPER PHILIP R P D 1.2 5,700 5,096,044 6,115,253
2017-08-22 4 HARPER PHILIP R P D 1.2 4,661 5,090,344 6,108,413
2017-08-10 4 HARPER PHILIP R P D 1.19 20,470 5,085,683 6,051,963
2017-04-28 4 BARER SOL J P D 1.5667 100,000 1,126,700 1,765,201
2017-04-26 4 BARER SOL J P D 1.5434 100,000 1,026,700 1,584,609
2017-03-24 4 HARPER PHILIP R P D 1.6 53,826 5,065,213 8,104,341
2017-03-23 4 HARPER PHILIP R P D 1.6 4,705 5,011,387 8,018,219
2017-03-22 4 HARPER PHILIP R P D 1.79 1,000,000 5,006,682 8,961,961
2016-12-08 4 GRANO JOSEPH J JR P D 5.266 -3,000 74,164 390,548
2015-10-06 4 COLA MICHAEL F P D 6.50 38,460 99,436 646,334
2015-10-06 4 NEIL GARRY ARTHUR P D 6.50 15,384 39,774 258,531
2015-10-06 4 GRANO JOSEPH J JR By family foundation P I 6.50 15,384 71,164 462,566
2015-10-06 4 BARER SOL J By wife P I 6.50 153,846 926,700 6,023,550
2015-09-21 4 BLECH ISAAC By Trust S I 9.96 -94,825 1,802,003 17,947,950
2015-09-21 4 BLECH ISAAC By Trust X I 4.10 230,357 1,896,828
2015-03-20 4 BAUER EUGENE A S D 8.45 -50,000 145,874 1,232,635
2015-03-20 4 BARER SOL J P D 8.45 50,000 772,854 6,530,616
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)
GNMX: Aevi Genomic Medicine Analysis and Research Report

2018-05-14 - Asif

Overview Aevi Genomic is a clinical stage biopharmaceutical company with an emphasis on identifying the genetic drivers of disease and applying this understanding to the pursuit of differentiated novel therapies primarily for pediatric onset, life-altering diseases, including rare and orphan diseases. The company look to find treatments for genetically defined diseases for which there are limited therapeutic options currently available, with a primary focus on pediatric patients. This strategy begins with identifying and genetically validating a therapeutic target and using genomics to guide product development. The strategy also involves identifying and acquiring otherwise abandoned or overlooked drug candidates and matching targets and mechanisms of action to novel genetic discoveries. Aevi Genomic has partnered with the Center for Applied Genomics, or CAG, at The Children’s Hospital of Philadelphia, or CHOP, to implement a genomic medicine driven approach to drug developm...

Related News Stories

Aevi Genomic Medicine (GNMX) Presents At Rodman & Renshaw.C. Wainwright 20th Annual Global Investment Conference - Slideshow

2018-09-06 seekingalpha
The following slide deck was published by Aevi Genomic Medicine, Inc. in conjunction with this event.

Evaluating KemPharm's KP415, Part 2: The History Of ADHD Treatment And The Competitive Landscape

2018-06-21 seekingalpha
KemPharm will soon publish the results of its Phase 3 clinical trial for KP415, a prodrug of dexmethylphenidate. (73-2)

Aevi Genomic Medicine: Try Subgroups Until It Works?

2018-05-20 seekingalpha
Aevi's current strategy has a reasonable chance of success, but the stock has several red flags and remains highly speculative. (20-1)